renal measure ambiguity
A percentage of normal is not a numeric eGFR cutoff
The source uses less than 30% of normal renal function. It does not state eGFR <30 mL/min/1.73 m2 or identify a conversion.
What to reconcileRetain the literal restriction and obtain product-specific clarification. Do not create a threshold by dropping the percent sign.
1 source identities and dates
GlobalRPh RX List - K-PHOS NEUTRALGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oral potassium/sodium phosphate product; not IV phosphate.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
dose table scope
FOLOTYN: reduced amount does not redefine the oncology cycle
The severe-renal per-administration dose retains the treatment schedule. ESRD avoidance with an exception is not an established dialysis dose.
What to reconcileUse the complete cycle and toxicity monitoring; do not manufacture an ESRD regimen.
1 source identities and dates
GlobalRPh RX List - FOLOTYNGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pralatrexate - FOLOTYN renal scope supplement; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
boundary units
GAVRETO: unusual printed boundary remains an evidence gap
The retrieved RX text prints less than 15 for the unstudied severe category while the supported range starts at 30. The 15-29 band is not silently repaired.
What to reconcileSeek exact official-label reconciliation before using this passage to assign a regimen in the gap.
1 source identities and dates
GlobalRPh RX List - GAVRETOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pralsetinib - GAVRETO capsules; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
dose table scope
Pramipexole IR: 14-day titration interval is not dosing every 14 days
Parkinson disease and RLS have separate instructions. The RLS renal interval concerns titration steps, while administration remains daily.
What to reconcileDo not transfer the Parkinson maximum or ER frequency to RLS; verify the indication-specific schedule.
1 source identities and dates
Pramipexole - immediate-release tabletsDailyMed / American Health Packaging | Source revision: Prescribing information revised October 2022.
Pramipexole dihydrochloride immediate-release oral tablets; adult Parkinson disease and separate RLS titration instructions. Not MIRAPEX ER. Selected sections, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
formulation
URL name does not establish immediate-release formulation
The /mirapex-drug/ page body reviewed for this import describes MIRAPEX ER.
What to reconcileUse this entry only for the extended-release product; do not transfer its renal schedule to immediate-release pramipexole.
1 source identities and dates
GlobalRPh RX List - Mirapex ERGlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval.
The RX List URL says mirapex, but its prescribing body is explicitly MIRAPEX ER. This record is ER only, not immediate-release.
Read this stored source Source difference identified; final patient-specific adjudication required. Added: vearlier.
formulation scope
MIRAPEX URL: retrieved body identifies extended release
The generic-looking mirapex URL displays MIRAPEX ER instructions. Its URL title is not sufficient evidence for immediate-release dosing.
What to reconcileUse this source only within its explicitly identified ER scope. Keep the separate official IR record and RLS instructions distinct.
1 source identities and dates
GlobalRPh RX List - MIRAPEX ERGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pramipexole - MIRAPEX ER source-identity warning; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
source scope and renal guidance
Daily total and overlapping source boundaries
Both selected tables express total mg/day and print overlapping endpoints at 30 and 60 mL/min. A daily amount is not a per-dose amount.
What to reconcileUse the indication-specific column, divide as directed, and clarify exact boundary values rather than silently normalizing them.
2 source identities and dates
GlobalRPh RX List - LYRICAGlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval
LYRICA immediate-release capsules and oral solution; adult renal adjustment.
Read this stored source LYRICA - official adult renal tableNational Library of Medicine / manufacturer labeling | Source revision: 4/2025
Immediate-release LYRICA capsules/oral solution; adult renal Table 2.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.1.
boundary units
LYRICA CR: formulation limits and the printed clearance-boundary overlap
The selected table overlaps at exactly CrCl 60. It directs use of an immediate-release product below the CR eligibility range and in hemodialysis.
What to reconcileDo not silently repair the boundary or substitute CR for IR milligram-for-milligram. Confirm the applicable full product instructions.
1 source identities and dates
GlobalRPh RX List - LYRICA CRGlobalRPh-hosted RX List | Source revision: RX page prints April 2025.
Pregabalin - LYRICA CR extended release; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
population scope
Pretomanid: combination treatment requires combination evidence
The selected renal limitations cover pretomanid and the companion regimen; they do not supply a dialysis protocol.
What to reconcileAssess the entire tuberculosis regimen with specialist input; do not infer a renal schedule.
1 source identities and dates
GlobalRPh RX List - PRETOMANIDGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pretomanid - tablets in a combination tuberculosis regimen; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
boundary units
MOTEGRITY: measured clearance and a separate official-source recovery
The official renal study used 24-hour urinary measured creatinine clearance. The short RX rendering did not supply its renal instructions and remains held.
What to reconcileKeep the official supplement and dialysis avoidance separate from the incomplete RX page. Do not silently relabel measured clearance as Cockcroft-Gault or indexed eGFR.
1 source identities and dates
Prucalopride - MOTEGRITY official labelDailyMed / Takeda Pharmaceuticals America, Inc. | Source revision: Prescribing information revised 7/2025.
Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
evidence limit
MESTINON: titrate response without inventing a renal percentage
The source advises that lower doses may be needed but supplies no fixed renal table.
What to reconcileConfirm formulation and titrate clinical effect; do not invent a reduction percentage.
1 source identities and dates
GlobalRPh RX List - MESTINONGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pyridostigmine - MESTINON oral products; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
historical source restriction
Historical IV quinidine is not current U.S. severe-malaria treatment
The old quinidine-injection renal caution is retained for historical context. CDC documents its discontinuation and identifies IV artesunate in current severe-malaria guidance.
What to reconcileDo not use this historical extract as a current malaria prescription. Follow the current CDC treatment pathway; the local summary is not a complete artesunate or follow-on regimen.
3 source identities and dates
GlobalRPh RX List - Quinidine injectionGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Historical quinidine gluconate injection source; current availability and clinical role not inferred.
Read this stored source CDC 2019 - IV quinidine discontinuation contextCDC | Source revision: March 28, 2019 (archived)
Historical IV quinidine for severe malaria, not oral quinidine antiarrhythmic products.
Read this stored source CDC 2026 - current severe-malaria pathway contextCDC | Source revision: August 17, 2026
Current U.S. severe-malaria guidance contrasted with historical IV quinidine; no patient-specific antimalarial order.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.5.
source identity ambiguity
Directory release-form wording is not enough to establish a regimen
The directory wording and retrieved sulfate page do not establish an exact extended-release product for these selected renal comments.
What to reconcileConfirm salt and release form before using a dosing schedule. Only the qualitative clearance caution is imported; no sulfate-to-gluconate or immediate-to-extended-release conversion is supplied.
1 source identities and dates
GlobalRPh RX List - Quinidine sulfateGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oral quinidine sulfate; release formulation needs exact-product reconciliation. Not quinidine gluconate ER or historical IV quinidine.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.5.
scope and safety
Creatinine secretion effect is not a blanket explanation for renal deterioration
The RX source distinguishes a small isolated creatinine change from the renal-failure warning. These statements address different clinical patterns.
What to reconcileAssess BUN, potassium, trajectory and clinical status; retain the source warning and avoid an invented renal reduction.
1 source identities and dates
GlobalRPh RX List - RANEXAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Ranolazine - RANEXA extended-release tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
evidence limit
ORGOVYX: PK similarity stops short of ESRD evidence
The studied CrCl range does not establish ESRD safety or a dialysis regimen.
What to reconcileKeep interaction review and unstudied dialysis populations explicit.
1 source identities and dates
GlobalRPh RX List - ORGOVYXGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Relugolix - ORGOVYX tablets; selected source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.9.
pk and monitoring
Unchanged parent PK does not remove sedation safeguards
The renal PK finding excludes dialysis and includes increased inactive-metabolite exposure.
What to reconcileDo not turn this finding into an automatic sedation regimen.
1 source identities and dates
GlobalRPh RX List - BYFAVOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
BYFAVO IV procedural sedation; selected renal PK finding only. Sedation monitoring and rescue capability remain essential.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.6.